Investments in Biotech: Italy experiences record financing!

Investments in Biotech: Italy experiences record financing!

On July 15, 2025, there are exciting news from the world of the venture capital and biotechnology in Italy. The Caffé di Bebeez illuminated the investment opportunities in the biotech sector on June 26, especially by looking at the Lighthouse Biotech case. The concentration on innovative solutions and sustainable technologies follows a constant flow of capital in this sector.

In a remarkable round, Angelini Ventures, Neva, Kurma Growth Opportunities Fund and Wellington Partners Þ secure a large series B financing of 84 million euros for nuclidium. They were supported by investors such as the Deep Tech & Climate Fund and Bavaria capital, who have all solid interest in biotechnology. Experienced heads such as Regina Hodits from Angelini Ventures and Liliana Nordbakk from Neva sit on the new board. A real profit for the innovative strength of the regions.

growth in the biotechnology sector

Italy's biotechnology, pharmaceutical and medical technology sector is developing rapidly, with cumulative investments of over 1.3 billion euros in the past ten years. In 2024, around 300 million euros accounted for life science start-ups. This is an increase of 60 % compared to the previous year! There is particularly exciting progress in the field of oncology, gene therapy and health technology. The Lombardy remains the hotspot for therapeutic agents, while Tuscany is leading in vaccine research.

In accordance with these developments, start-ups such as Chloris have geospatial, which recently secured $ 8.5 million in a series, exploit the potential to put innovative solutions into practice. Tulum Energy also stands out after it has raised $ 27 million for its new technologies. CEO Massimiliano Pieri and Cto Donald Kendrick emphasize the goal of promoting their technologies.

venture capital in Italy

The investment environment for biotech startups is booming thanks to a variety of venture capital funds that are active in this area. The most remarkable actors include Sofinnova Partners, CDP Venture Capital SGR and IAG, all of which invest in different altitudes of the biotech sector. In a list that is updated monthly, over 50 VC funds are recorded, including funds invested directly in Italian biotech companies.

Above all, intellectual property (IP) plays a key role in the structure of VC transactions. It not only affects the company value, but also the conditions of the deals considerably. The reform of the "Professor privilege", which came into force in 2023, changed IP rights in universities and research institutions and created new marketing options. This change ensures that investors have to deal intensively with the ownership issues and the use of IP to protect their investments.

With the steadily growing interest in biotechnology, it is clear that the future for investments in Italian start-ups also looks rosy. Angelini, Neva and other venture capital companies are on the right track of not only achieving economic successes with their investments in biotech startups, but also contributing to medical innovation.

Bebeez reports in detail about the current investment situation, while Shizune offers a comprehensive list of VC funds for the biotechnology sector. For a deeper insight into the growing biotech ecosystem in Italy iba with analyzes and market data.